



The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis

Yan Li^{1,2†}, Meizhi He^{2†}, Yaoyao Zhou², Chen Yang³, Shuyi Wei², Xiaohui Bian², Odong Christopher³ and Lang Xie^{1*}

¹ Department of General Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou, China, ² The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China, ³ The First School of Clinical Medicine, Southern Medical University, Guangzhou, China

OPEN ACCESS

Edited by:

Hubing Shi, Sichuan University, China

Reviewed by:

Jinhua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, China Yeye Guo, Central South University, China

> ***Correspondence:** Lang Xie langxiezj@hotmail.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

> Received: 15 September 2018 Accepted: 06 February 2019 Published: 28 February 2019

Citation:

Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O and Xie L (2019) The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Front. Pharmacol. 10:139. doi: 10.3389/fphar.2019.00139 **Background:** Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients.

Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA).

Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% Cl 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% Cl 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% Cl 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% Cl 1.57–3.60, P < 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage.

Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H).

Keywords: colorectal cancer, PD-L1/ PD-1, prognostic, clinicopathological, meta-analysis

Globally, colorectal cancer (CRC) is the third leading cause of cancer (Siegel et al., 2017). Although cancer screening programs and the standardization of preoperative and postoperative care have reduced mortality associated with a CRC diagnosis (Welch and Robertson, 2016), CRC is still a leading cause of cancer-related deaths worldwide, for it has a poor prognosis in its malignant stages and recurrence is common. Therefore, it is essential to identify new biomarkers to improve clinical decision-making and patient outcomes.

As one of the most possible newly biomarkers to evaluate cancer patients' outcomes, programmed death 1 (PD-1) is an immune-inhibitory receptor that is expressed on the surface of activated T cells as a result of persistent inflammatory stimuli (Inaguma et al., 2016; Zou et al., 2016). PD-L1 is expressed by T and B cells, macrophages and dendritic cells and its expression implies a weakened host immune response and consequent a poor prognosis (Hansen et al., 2009). The binding of PD-L1 to PD-1 can attenuate the cellular immune response by reducing T cells apoptosis or exhaustion. Blockade of the PD-1/PD-L1 pathway with monoclonal antibodies is a highly promising therapy and prominent clinical benefits of this checkpoint-blockade were observed in recent clinical trials (Zheng and Zhou, 2015; Wang et al., 2018).

Positive PD-L1 expression has been associated with significantly poor prognoses; however, studies evaluating the prognostic significance of PD-L1 expression in CRC are limited and remain controversial. Therefore, we conducted a comprehensive meta-analysis to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients.

MATERIALS AND METHODS

Literature Search

Two authors (M. Z. He and Y. Y. Zhou) independently conducted comprehensive literature searches of published articles using the Medline/PubMed, Embase, Cochrane Library, WoS and Scopus databases. The endpoint for search items was July 21, 2018. The following keywords were used: ("colorectal" OR "colorectum" OR "colon" OR "Rectum" OR "Rectal" OR "large intestine") AND ("adenocarcinoma?" OR "tumor?" OR "neoplasm?" OR "carcinoma?" OR "cancer?" OR "malignant") AND ("Programmed Cell Death 1 Receptor" OR "CD279 Antigen" OR "PD-1" OR "B7-H1 Antigen" OR "Programmed Cell Death 1 Ligand 1" OR "PD-L1 "OR "CD 274"). Titles and abstracts were screened through NoteExpress and any discrepancies were resolved by mutual discussion.

Eligibility Criteria

The criteria for inclusion were: (1) All patients were histologically confirmed as having CRC and had not received adjuvant chemotherapy before surgery; (2) PD-L1 expression was detected by immunohistochemistry (IHC); (3) Studies showed a correlation between PD-L1 expression with clinicopathological features and/ or prognoses; (4) Articles were published as a full paper in English. The criteria for exclusion were: (1) Case reports, reviews and letters; (2) The main content did not evaluate the relationship of PD-L1 expression with clinicopathological features and/ or prognoses; (3) duplications and studies without eligible data. When duplicate publications were identified, only the article with the newest and most comprehensive information was included.

Data Extraction and Quality Assessment


The following information from the included articles was extracted by two reviewers (M. Z. He and Y. Y. Zhou): name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cutoff values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score. Any disagreements between the two reviewers were resolved by consensus involving a third reviewer (Y. Li). Outcome parameters comprised OS, DFS and recurrence-free survival (RFS). The HRs and 95% confidence intervals (CIs) were evaluated for outcome parameters. If the HRs were not available, we extracted data from survival curves or contacted the corresponding authors.

According to the Newcastle-Ottawa Quality Assessment (NOS), a quality assessment was independently carried out for the included articles by two authors (M.Z. He and Y. Y. Zhou). Discrepancies in scoring were resolved by discussion and consensus. The NOS consists of the following three parameters of quality: selection, comparability and outcome. The maximum NOS score is nine points, with studies scoring greater than six considered to be of high quality (Stang, 2010).

Statistical Methods

Pooled HRs and 95% CIs were calculated to evaluate the association between PD-L1 positive expression with OS, DFS, RFS and clinicopathological parameters. Heterogeneity among studies was evaluated using the Chi-squared test and I^2 . A random-effects model was used when there was evidence of significant heterogeneity ($I^2 > 50\%$ or *P*-value <0.1). In all other cases, a fixed-effects model was used. Potential publication bias was assessed through Egger's and Begg's tests. The statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). All *P*-values and 95% CIs were two-sided, and *P*-values< 0.05 were considered to be statistically significant.

Abbreviations: PD-L1, programmed death-ligand 1; CRC, colorectal cancer; WoS, wet of science; HR, hazard ratio; TCs, tumor cells; OS, overall survival; DFS, disease-free survival; ORs, odds ratios; T stage, tumor stage; TNM, tumornode-metastasis; MSI-H, microsatellite instability high; PD-1, programmed death 1; IHC, immunohistochemistry; CIs, confidence intervals; NOS, newcastleottawa quality assessment; IRS, immunoreactivity score; TILs, tumor-infiltrating lymphocytes; CTLs, CD8+ cytotoxic T lymphocytes; CTLA4, CTL-associated antigen 4; IDO1, indoleamine 2,3-dioxygenase 1; TIME, tumor immunity in the microEnvironment; mPD-L1, PD-L1 promoter methylation.



RESULTS

Search Results and Study Characteristics

After exclusion of 626 duplicates, 3,356 articles about PD-1/PD-L1 in colorectal cancer were identified from a primary system literature search in the Medline/PubMed, Embase, Cochrane Library, WoS, and Scopus databases. The titles and abstracts of the remaining articles were screened, and 2,985 records were rejected because they were case reports, letters, meeting, reviews or not in the fields of interests. We read 371 records for further assessment. Among them, 319 full-text articles were not available, another 40 lacked eligible data, and two scored lower than 6 on the NOS. Finally, 10 articles were included in this meta-analysis. A flowchart of the literature selection is shown in **Figure 1**.

The characteristics of the 10 included studies are listed in **Table 1**. These included studies were generally of high quality, with NOS scores ranging from six to eight. All 10 studies were retrospective and published between 2013 and 2018. In total, 10 studies comprising 2,131 patients were included in the pooled analysis and all selected studies used IHC assays to evaluate PD-L1 expression in tumor cells and /or TILs. Each article had an independent cut-off value used to define the criterion for PD-L1 positive. Six studies provided OS data (Shi et al., 2013; Zhu et al., 2015; Li et al., 2016; Enkhbat

et al., 2018; Lee S. J. et al., 2018; Liu et al., 2018), three studies included DFS data (Enkhbat et al., 2018; Lee K. S. et al., 2018; Lee S. J. et al., 2018) and three studies included RFS data (Lee et al., 2016; Wang et al., 2016, 2017). In addition, HRs and 95% CIs were abstracted directly from the 10 included studies.

Association Between PD-L1 Expression and Prognostic Parameters

We evaluated the association between PD-L1 expression and prognostic parameters (OS, DFS and RFS). The pooled HR for OS in TC from six studies, involving 1,131 patients, showed that PD-L1 expression was significantly associated with poor OS in CRC (HR = 1.50, 95%CI 1.05–2.13, P = 0.03; see **Figure 2A**). When we took Immunoreactivity score (IRS) ≥ 4 as the cut-off value, we found shorter survival in the PD-L1 positive group (HR = 2.65, 95%CI 1.44–4.86, P = 0.002; see **Figure 2B**). The pooled HR for DFS in TC with 452 patients indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95%CI 1.40–4.75, P = 0.002; see **Figure 2C**). The pooled HR for RFS in TC with 657 patients (HR = 2.38, 95%CI 1.14–4.96, P = 0.02; see **Figure 2D**) as well as the pooled HR for RFS in tumor-infiltrating lymphocytes (TILs) with 516 CRC patients (HR = 1.79, 95%CI

TABLE 1 Main characteristics of the studies included for meta-analysis.
--

References	Country	No.	Tumor Histology	Stage	Technique	Cut-off	PD-L1(+) (%)	Outcome	HR estimation (95% CI)	Quality assessment (score)
Shi et al., 2013	China	143	CRC	I-IV	IHC	Moderate or intense staining	TC: 64/143(44.8)	OS	TC: 2.77(1.05–2.99)	6
Zhu et al., 2015	China	120	SAC	NA	IHC	$IRS \ge 4$	TC: 28/120(23.3)	OS	TC: 2.30(1.13-4.68)	7
Lee et al., 2016	USA	395	CRC	I-IV	IHC+TMA	≥10% and intense staining	TC: 19/394(4.8)	RFS	TC: 22.86(1.99–263.21)	6
Wang et al., 2016	Switzerland	262	CRC	-	IHC+TMA	≥5%	TILs: 54/262(20.6)	RFS	TC: 1.90(0.88–4.14) TILs: 1.83(1.09–3.05)	7
Wang et al., 2017	China	254	CRC	-	IHC+TMA	NA	TILs: 89/254(35.0)	RFS	TILs: 1.74(1.02–2.98)	6
Li et al., 2016	China	356 (TCGA)	CRC	NA	IHC+TMA	IRS> 4	TC: 301/356(84.6)	OS	TC: 0.63 (0.33-1.18)	8
Enkhbat et al., 2018	Japan	116	CRC	11-111	IHC	IRS≥ 4	TC: 52/116(44.8)	OS DFS	OS: TC:3.87(1.19–12.57) DFS: TC:1.91(0.81–4.52)	6
Liu et al., 2018	China	60	mCRC	NA	IHC	$IS \ge 3$	TC: 26/60(43.3)	OS	TC:0.28(0.08-0.99)	6
Lee K. S. et al., 2018	South Korea	89	CC(MSI)	1-111	IHC	≥5%	TILs: 56/89(62.9)	DFS	TILs:0.33(0.11-0.80)	6
Lee S. J. et al., 2018	South Korea	336	CRC	0-IV	IHC+TMA	≥1%	TC: 15/336(9.4)	OS DFS	OS: TC:3.78(1.45–9.90) DFS: TC:3.50(1.46–8.41)	7

CRC, colorectal cancer; SAC, serrated adenocarcinoma; mCRC, metastatic colorectal cancer; CC, colon cancer; MSI, microsatellite instability; IHC, immunohistochemistry; NA, not available; TMA, tissue microarray; OS, overall survival; HR, hazard ratio; TC, tumor cell; TILs, tumor-infiltrating lymphocytes; IRS, Immunoreactivity score; IS, Immunoscore; DFS, disease-free survival; RFS, recurrence-free survival.

1.23–2.95, P = 0.002; see **Figure 2E**) showed that PD-L1 expression was significantly associated with poor RFS both in TC and TILs.

Association Between PD-L1 Expression and Clinicopathological Characteristics Gender

The association between PD-L1 expression and gender was evaluated in eight studies, comprising 3,477 patients. 320(31.37%) of 1,020 male patients and 241(31.42%%) of 767 female patients were PD-L1 expression positive. The pooled OR showed that there was no significant association found between PD-L1 expression and gender (OR = 1.00, 95%CI 0.76–1.31, *P* = 0.98; see **Figure 3A**).

Age

We evaluated the association between PD-L1 expression and age in a total of 405 patients from two studies. 49 (26.78%) of 183 younger patients (<60 years of age) were PD-L1 expression positive and 69 (31.08%) of 222 older patients (\geq 60 years of age) were PD-L1 expression positive. There was no significant association found between PD-L1 expression and age (OR = 1.41, 95% CI 0.90–2.23, *P* = 0.13; see **Figure 3B**).

Cancer Location

The association between PD-L1 expression and cancer location was analyzed in six studies with a population of 1,025 patients. Of 344 right colon cancer patients, 65 (18.90%) were PD-L1 expression positive, while 77(11.31%) in 681 left colon/rectum cancer patients. The pooled OR showed a significant association between PD-L1 expression and cancer location (OR = 2.38, 95% CI 1.57–3.60, P < 0.0001; see **Figure 3C**).

Differentiation

Of 1,066 well/moderately differentiated tumors, 159 (14.92%) were PD-L1 expression positive. Of 154 poorly differentiated tumors, 49 (34.82%) were PD-L1 expression positive. The pooled OR showed that PD-L1 expression was significantly associated with differentiation based on pooled data from five studies (OR = 3.47, 95%CI 1.37–8.77, P = 0.008; see **Figure 3D**).

Tumor Size

Only two studies, including 382 colorectal cancer patients, analyzed the subgroup of tumor size based on the cut-off value of 5 cm. 36 (25.17%) of 143 patients with large tumors (\geq 5 cm) and 48 (20.01%) of 239 patients with small tumors (<5 cm) were PD-L1 expression positive. The pooled results carried out in a fixed effect model, showed that there was no significant association

			Hazard Ratio		Hazard Ratio	
Study or Subgroup	•• •	Weight	IV, Fixed, 95% CI		IV, Fixed, 95% Cl	
Enkhabt 2018	1.354 0.6008		3.87 [1.19, 12.57]			
_ee 2018b	1.331 0.4906	13.6%	3.78 [1.45, 9.90]			
_i 2016T	-0.4684 0.3236	31.3%	0.63 [0.33, 1.18]			
₋iu 2018	-1.2874 0.6513	7.7%	0.28 [0.08, 0.99]			
Shi 2013	1.0192 0.4961	13.3%	2.77 [1.05, 7.33]			
Zhu 2015	0.8346 0.3621	25.0%	2.30 [1.13, 4.68]			
Total (95% CI)		100.0%	1.50 [1.05, 2.13]		▲	
	3.03, df = 5 (P = 0.0003); l ² = 7	78%	0.0)1	0.1 1 10	100
est for overall effect: Z	Z = 2.22 (P = 0.03)				PD-L1 positive PD-L1 negative	
			Hazard Ratio		Hazard Ratio	
Study or Subgroup	log[Hazard Ratio] SE	Weigh			IV. Fixed, 95% CI	
Enkhabt 2018	1.354 0.6008	-				
Zhu 2015	0.8346 0.3621		and the second sec			
Lnu 2015	0.8346 0.3621	73.47	6 2.30 [1.13, 4.68]		_	
Fotal (95% CI)		100.0%	6 2.65 [1.44, 4.86]		•	
. ,	0.55, df = 1 (P = 0.46); l ² = 09	%		—		
Test for overall effect:		10.751		0.01	0.1 1 10	100
	/				PD-L1 positive PD-L1 negative	
			Hazard Ratio		Hazard Ratio	
tudy or Subgroup	log[Hazard Ratio] SI	E Weigh	t IV, Fixed, 95% C	1	IV, Fixed, 95% CI	
Enkhabt 2018	0.6487 0.4378	3 51.0%				
.ee 2018b	1.2539 0.4463				— ∎ —	
00 20 100	1.2000 0.1100	10.07	0.00[1.10, 0.10]			
Fotal (95% CI)		100.09	% 2.57 [1.40, 4.75]			
		0/_		H		— I
	0.94. df = 1 (P = 0.33); $I^2 = 0^{10}$					
leterogeneity: Chi ² =	0.94, df = 1 (P = 0.33); $I^2 = 0^{-1}$ Z = 3.03 (P = 0.002)	70		0.01	0.1 1 10	100
		70		0.01	0.1 1 10 PD-L1 positive PD-L1 negative	100
Heterogeneity: Chi ² =		70	Hazard Ratio	0.01		100
Heterogeneity: Chi ² = Fest for overall effect:	Z = 3.03 (P = 0.002)	Weight			PD-L1 positive PD-L1 negative	100
Heterogeneity: Chi ² =	Z = 3.03 (P = 0.002)	Weight		1	PD-L1 positive PD-L1 negative Hazard Ratio	100
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016	Z = 3.03 (P = 0.002)	Weight	IV, Fixed, 95% C	1	PD-L1 positive PD-L1 negative Hazard Ratio	100
Heterogeneity: Chi ² = Fest for overall effect: Study or Subgroup	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456	Weight 9.0%	IV. Fixed, 95% C 22.86 [1.99, 262.63]	1	PD-L1 positive PD-L1 negative Hazard Ratio	100
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456	Weight 9.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10]	1	PD-L1 positive PD-L1 negative Hazard Ratio	100
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Nang 2016 Total (95% CI)	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456	Weight 9.0% 91.0% 100.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10]	<u>ı</u>	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Nang 2016 Total (95% CI)	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴	Weight 9.0% 91.0% 100.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10]	1	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI	100
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Nang 2016 Fotal (95% CI) Heterogeneity: Chi ² = 3	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴	Weight 9.0% 91.0% 100.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96]	<u>ı</u>	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup ee 2016 Vang 2016 Total (95% CI) Heterogeneity: Chi ² = 3 Test for overall effect: 3	Z = 3.03 (P = 0.002) <u>log[Hazard Ratio]</u> SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴ Z = 2.31 (P = 0.02)	<u>Weight</u> 9.0% 91.0% 100.0% %	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio	0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Nang 2016 Total (95% CI) Heterogeneity: Chi ² = 3 Fest for overall effect: 3 Study or Subgroup	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); I ² = 72 ⁴ Z = 2.31 (P = 0.02) log[Hazard Ratio] SE	<u>Weight</u> 9.0% 91.0% 100.0% %	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio t. IV. Fixed, 95% C	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI	→
teterogeneity: Chi ² = est for overall effect: tudy or Subgroup tee 2016 Vang 2016 Total (95% CI) teterogeneity: Chi ² = 3 fest for overall effect: 3 Study or Subgroup	Z = 3.03 (P = 0.002) <u>log[Hazard Ratio]</u> SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴ Z = 2.31 (P = 0.02)	<u>Weight</u> 9.0% 91.0% 100.0% %	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio t. IV. Fixed, 95% C	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup ee 2016 Nang 2016 Total (95% CI) Heterogeneity: Chi ² = 3 Fest for overall effect: 3	Z = 3.03 (P = 0.002) log[Hazard Ratio] SE 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); I ² = 72 ⁴ Z = 2.31 (P = 0.02) log[Hazard Ratio] SE	<u>Weight</u> 9.0% 91.0% 100.0% % <u>= Weigh</u> 51.9%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio t IV. Fixed, 95% C 4 1.83 [1.09, 3.07]	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Wang 2016 Fotal (95% CI) Heterogeneity: Chi ² = 3 Fest for overall effect: 3 Study or Subgroup Wang 2016 Wang 2017	Z = 3.03 (P = 0.002) $log[Hazard Ratio] SE$ 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴ $Z = 2.31 (P = 0.02)$ $log[Hazard Ratio] SE$ 0.6043 0.2644	<u>Weight</u> 9.0% 91.0% 100.0% % <u>E Weigh</u> 51.9% 7 48.1%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio tt IV. Fixed. 95% C 6 1.83 [1.09, 3.07] 6 1.74 [1.02, 2.98]	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→
Heterogeneity: Chi² = Test for overall effect: Study or Subgroup Lee 2016 Vang 2016 Total (95% CI) Heterogeneity: Chi² = 3 Test for overall effect: 3 Study or Subgroup Wang 2016 Vang 2016 Vang 2016 Vang 2016 Vang 2017 Total (95% CI)	Z = 3.03 (P = 0.002) $log[Hazard Ratio] SE$ 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴ 3.63, df = 1 (P = 0.02) $log[Hazard Ratio] SI$ 0.6043 0.2644 0.5533 0.2747	Weight 9.0% 91.0% 100.0% % <u>E Weigh</u> 51.9% 7 48.1% 100.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio tt IV. Fixed. 95% C 6 1.83 [1.09, 3.07] 6 1.74 [1.02, 2.98]	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→
Heterogeneity: Chi ² = Test for overall effect: Study or Subgroup Lee 2016 Wang 2016 Total (95% CI) Heterogeneity: Chi ² = 3 Fest for overall effect: Study or Subgroup Wang 2016 Wang 2017 Total (95% CI)	Z = 3.03 (P = 0.002) $log[Hazard Ratio] SE$ 3.1294 1.2456 0.6419 0.3927 3.63, df = 1 (P = 0.06); l ² = 72 ⁴ $Z = 2.31 (P = 0.02)$ $log[Hazard Ratio] SE$ 0.6043 0.2644	Weight 9.0% 91.0% 100.0% % <u>E Weigh</u> 51.9% 7 48.1% 100.0%	IV. Fixed. 95% C 22.86 [1.99, 262.63] 1.90 [0.88, 4.10] 2.38 [1.14, 4.96] Hazard Ratio tt IV. Fixed. 95% C 6 1.83 [1.09, 3.07] 6 1.74 [1.02, 2.98]	I 0.01	PD-L1 positive PD-L1 negative Hazard Ratio IV. Fixed, 95% CI 0.1 1 10 PD-L1 positive PD-L1 negative Hazard Ratio	→

FIGURE 2 | Forest plot of 10 studies evaluating the association between PD-L1 expression and prognostic parameters in CRC patients (A: OS in TC; B: IRS≥4 as cut-off value; C: DFS in TC; D: RFS in TC; E: RFS in TILs).

between PD-L1 expression and tumor size (OR = 1.31, 95%CI 0.80-2.14, P = 0.29; see Figure 3E).

T Stage

We evaluated the association between PD-L1 expression and T stage in 1,716 patients. Of 283 Tis-T2 stage patients, 82 (28.98%) were PD-L1 expression positive and 454 (31.68%) of 1,433 T3-T4 stage patients were PD-L1 expression positive. The pooled HR showed that there was no significant association between PD-L1 expression and T stage (OR = 1.02, 95%CI 0.68–1.54, P = 0.93; see **Figure 3F**).


Lymph Node Metastasis

The association between PD-L1 expression and lymph node metastasis was evaluated in six studies (1,589 patients). The pooled OR indicated that there was no significant association found between PD-L1 expression and lymph node metastasis (OR = 1.23, 95%CI 0.71–2.12, P = 0.46; see **Figure 3G**).

TNM Stage

Six studies, involving 1,329 patients, evaluated the association between PD-L1 expression and TNM stage in a fixed effects model. 138 (21.26%) of 649 stage I-II patients and 122 (17.94%) of 680 stage III-IV patients were PD-L1 expression positive. The

		Total	Fema Events		Weight	Odds Ratio M-H, Fixed, 95% 0		м	Odds Ratio H. Fixed, 95%	CI	
.ee 2016 .ee 2018b	Events 35	79	17	37	12.2%	0.94 [0.43, 2.05		a			
.ee 2018b	5	200	14	194	13.1%	0.33 [0.12, 0.93		-	•		
	7	201	8	135	8.7%	0.57 [0.20, 1.62		-	-		
.i 2016T	166	199	135	157	23.7%	0.82 [0.46, 1.47			_		
.iu 2018	20	43	6	17	4.4%	1.59 [0.50, 5.09					
Shi 2013 Wang 2016	30 37	61 166	34 17	82 96	14.0% 15.9%	1.37 [0.70, 2.66			+		
Zhu 2015	20	71	10	49	8.0%	1.53 [0.64, 3.64			+		
	20		10	40	0.070	1.00 [0.04, 0.04	1				
Total (95% CI)		1020		767	100.0%	1.00 [0.76, 1.31]	1		+		
Total events	320		241								
Heterogeneity: Chi ² = 9				23%			0.01	0.1	1	10	100
Test for overall effect:	Z = 0.03 (I	P = 0.9	8)				0101	011	Male Female	10	100
3	≥60 ye		<60 ye	ars		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight			M	H. Fixed, 95% (
Shi 2013	34	69	30	74	46.2%	1.42 [0.74, 2.76			-		
Wang 2016	35	153	19	109	53.8%	1.40 [0.75, 2.62]		-		
				100							
Fotal (95% CI) Fotal events	69	222	49	183	100.0%	1.41 [0.90, 2.23]	0				
Heterogeneity: Chi ² = (1 (P = (0%			H		_		
Test for overall effect:				070			0.01	0.1	1	10	100
			-/					≥60	years <60 yea	irs	
;	Right col		Left color			Odds Ratio			Odds Ratio		
		Total	Events	Т	otal We				M-H. Fixed, 95%	CI	
Enkhabt 2018	24	37	28			.2% 3.36 [1.48, 7					
.ee 2016 .ee 2018b	12 9	154 96	7			.9% 2.80 [1.08, 7 .0% 4.03 [1.40, 11					
iu 2018	6	16	20			.6% 0.72 [0.22, 2					
Zhu 2015	14	41	16			.4% 2.04 [0.88, 4			-		
Fotal (95% CI)		344			681 100	2.38 [1.57, 3.	60]		•		
Fotal events	65	0	77				<u> </u>			_	
Heterogeneity: Chi ² = 5. Fest for overall effect: Z	86, df = 4	(P = 0.2	(1); I ² = 32	%			0.01	0.1	1	10	100
est for overall effect: Z	- 4.09 (P	~ 0.000	")					Rig	ht colon Left co	Ion/Rectu	m
)	Poor		Vell/mode	erate		Odds Ratio			Odds Ratio		
	Events 1		Events	Total	Weight	M-H, Random, 95%	CI	M	H. Random, 95%	6 CI	
.ee 2016	7	54	12	336	20.7%	4.02 [1.51, 10.3	73]		-	_	
.ee 2018a	14	18	42	71	18.5%	2.42 [0.72, 8.0				_	
.ee 2018b	6	17	9	319	18.6%	18.79 [5.69, 62.0	[80			_	
Shi 2013	11 11	16 49	53 43	127 213	19.4% 22.9%	3.07 [1.01, 9.3 1.14 [0.54, 2.4					
Wang 2016		49	43	213	22.9%	1.14 [0.54, 2.4	+2]				
Total (95% CI)		154		1066	100.0%	3.47 [1.37, 8.7	71		-		
Fotal events	49		159								
Heterogeneity: Tau ² = 0	.83; Chi ² =	16.25,	df = 4 (P	= 0.003	s); l² = 75	%	0.01	0,1		10	100
Test for overall effect: Z	:= 2.63 (P	= 0.008	3)				0.01	0.1	Poor Well/m		100
	≥5cr					Odds Ratio					
Study or Subgroup	≥5cr Events		<5cm Events		Weight		1	м	Odds Ratio H. Fixed, 95% (1	
Wang 2016	22	89	32	173	60.5%	1.45 [0.78, 2.68]					
Zhu 2015	14	54	16	66	39.5%	1.09 [0.48, 2.51]			_ _		
	14	04	10	00	00.070	1.00 [0.40, 2.01]					
Total (95% CI)		143		239	100.0%	1.31 [0.80, 2.14]			+		
Total events	36		48								
Heterogeneity: Chi ² = (0%			0.01	0.1	1	10	100
Test for overall effect:	Z = 1.06 (I	P = 0.2	9)				0.01		≥5cm	10	100
-	-										
Study or Subgroup	T3-4 Events		Tis-2 Events		Weight	Odds Ratio M-H, Fixed, 95% (м	Odds Ratio H. Fixed, 95%	21	
		TOtal	Events			m-n. Fixed, 55% (
	48	108	4			0 80 10 10 3 37					
Enkhabt 2018	48	108	4	8	9.2%	0.80 [0.19, 3.37		-	-		
Enkhabt 2018 .ee 2016	11	289	7	8 94	22.6%	0.49 [0.18, 1.31	j	-	-		,
Enkhabt 2018 Lee 2016 Lee 2018b	11 15	289 270	7 0	8 94 66	22.6% 1.7%	0.49 [0.18, 1.31 8.07 [0.48, 136.60]	-	-		
Enkhabt 2018 .ee 2016	11	289	7	8 94	22.6%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73]]	-			
Enkhabt 2018 Lee 2016 Lee 2018b Li 2016T	11 15 242	289 270 288	7 0 59	8 94 66 68	22.6% 1.7% 33.8%	0.49 [0.18, 1.31 8.07 [0.48, 136.60]]]	-			
Enkhabt 2018 Lee 2016 Lee 2018b Li 2016T Shi 2013	11 15 242 61	289 270 288 128	7 0 59 5	8 94 66 68 15	22.6% 1.7% 33.8% 10.4%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63]]]]	-			,
Enkhabt 2018 Lee 2016 Lee 2018b Li 2016T Shi 2013 Wang 2016 Zhu 2015	11 15 242 61 49	289 270 288 128 247 103	7 0 59 5 5	8 94 66 68 15 15 15	22.6% 1.7% 33.8% 10.4% 16.8% 5.5%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03]]]]	-			
Enkhabt 2018 Lee 2016 Lee 2018b Li 2016T Shi 2013 Wang 2016 Zhu 2015 Fotal (95% CI)	11 15 242 61 49 28	289 270 288 128 247	7 0 59 5 5 2	8 94 66 68 15 15	22.6% 1.7% 33.8% 10.4% 16.8%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03]]]]	-	•		,
Enkhabt 2018 .ee 2016 .ee 2018b .i 2016T Shi 2013 Wang 2016 2hu 2015 Fotal (95% CI) Fotal events	11 15 242 61 49 28 454	289 270 288 128 247 103 1433	7 0 59 5 5 2 82	8 94 66 15 15 17 283	22.6% 1.7% 33.8% 10.4% 16.8% 5.5%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03]]]]	-			
Enkhabt 2018 .ee 2018 .iee 2018b .i 2016T Shi 2013 Wang 2016 Zhu 2015 Total (95% CI) Fotal events Teterogeneity: Chi ² = 4	11 15 242 61 49 28 454 8.95, df =	289 270 288 128 247 103 1433 6 (P = 1	7 0 59 5 2 2 82 0.18); ² =	8 94 66 15 15 17 283	22.6% 1.7% 33.8% 10.4% 16.8% 5.5%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03]]]]				→ 100
Enkhabt 2018 .ee 2016 .ee 2018b .i 2016T Shi 2013 Wang 2016 2hu 2015 Fotal (95% CI) Fotal events	11 15 242 61 49 28 454 8.95, df =	289 270 288 128 247 103 1433 6 (P = 1	7 0 59 5 2 2 82 0.18); ² =	8 94 66 15 15 17 283	22.6% 1.7% 33.8% 10.4% 16.8% 5.5%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03		-	1 T3-4 Tis-2		
Enkhabt 2018 .ee 2018 .ee 2018b .i 2016T Shi 2013 Vang 2016 Zhu 2015 Fotal (95% CI) Fotal (95% CI) Fotal events Heterogeneity: Chi ² = 1 Fest for overall effect: .	11 15 242 61 49 28 454 8.95, df = (Z = 0.09 ((289 270 288 128 247 103 1433 6 (P = 0 P = 0.9	7 0 59 5 2 2 0.18); ² = 3) N-	8 94 66 68 15 15 17 283 33%	22.6% 1.7% 33.8% 10.4% 16.8% 5.5%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54])))) 0.01		Odds Ratio	 10	
Enkhabt 2018 .ee 2016 .ee 2018b .i 2016T Shi 2013 Wang 2016 Zhu 2015 Fotal (95% CI) Fotal events Heterogeneity: Chi ² = 1 Fest for overall effect: .	111 15 242 61 49 28 454 8.95, df = Z = 0.09 (l N+ Events	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total	7 0 59 5 2 0.18); ² = 3) N- Events	8 94 66 68 15 15 17 283 33%	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] Odds Ratio M-H, Random, 95%	0 0 0.01			 10	
Enkhabt 2018 .ee 2016 .ee 2018 J. 2016T Shi 2013 Zhu 2015 Total (95% CI) Total events Heterogeneity: Chi ² = 1 Fest for overall effect: Study or Subgroup	111 15 242 61 49 28 454 8.95, df = Z = 0.09 (I N+ Events 9	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185	7 0 59 5 2 0.18); I ² = 3) N- Events 9	8 94 66 15 15 17 283 33% <u>Total</u> 187	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight_ 14.5%	0.49 [0.18, 1.31 8.07 [0.48, 136.00 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] Odds Ratio M-H. Random. 95% 1.01 [0.39, 2.6)))) 0.01 CI		Odds Ratio	 10	
Enkhabt 2018 ee 2018 ee 2018 1.2016T Shi 2013 Nang 2016 Zhu 2015 Fotal (98% CI) fotal events Heterogeneity: Ch ² = 1 Fest for overall effect: Study or Subgroup ee 2016	111 15 242 61 49 28 454 8.95, df = 1 Z = 0.09 (I <u>R+</u> <u>Events</u> 9 11	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185 174	7 0 59 5 2 82 0.18); ² = 3) N- Events 9 4	8 94 66 15 15 17 283 33% <u>Total</u> 187 162	22.6% 1.7% 33.8% 10.4% 5.5% 100.0% <u>Weight</u> 14.5% 11.8%	0.49 [0.18, 1.31 8.07 [0.48, 136.00 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] Odds Ratio M-H. Random. 55% 1.01 [0.39, 2.6 2.67 [0.38, 6.5	0.01		Odds Ratio	 10	
Enkhabi 2018 .ee 2016 .ee 2017 J.2016T Shi 2013 Wang 2016 Zhu 2015 Total (95% C1) Total events Heterogeneity: Chi ² = 1 est for overal effect: Study or Subgroup .ee 2016 .ee 2018b J.2016T	11 15 242 61 49 28 454 8.95, df = I Z = 0.09 (I Z = 0.09 (I N+ Events 9 9 11 11 330	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185 174 162	7 0 59 5 2 2 0.18); ² = 3) N- Events 9 9 4 171	8 94 66 68 15 17 283 33% Total 187 162 194	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% <u>Weight</u> 14.5% 11.8% 19.9%	0.49 [0.18, 1.31 8.07 [0.48, 136.00 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] 0.04ds Ratio M-H. Random, 95% 1.01 [0.39, 2.6 2.67 [0.33, 6.9	CI CI 1] 0.01		Odds Ratio	 10	→ 100
Enkhabi 2018 ee 2018 ee 2018 1.2016T Shi 2013 Fotal (95% CI) Total (95% CI) Total (95% CI) Total events Heterogeneity: Chi ² = 1 Gest for overall effect: ee 2018 e.ee 2018 J.2016T J.2016T	11 15 242 61 49 28 454 8.95, df = Z = 0.09 (I N+ Events 9 11 130 31	289 270 288 247 103 1433 6 (P = 0 P = 0.9 Total 185 174 162 71	7 0 59 5 2 2 0.18); I ² = 3) N- Events 9 4 171 33	8 94 66 68 15 15 17 283 33% Total 187 162 194 72	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 18.7%	0.49 [0.18, 1.31 6.07 [0.48, 1.36 60 0.80 [0.37, 1.73 1.82 [0.59, 5.53 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] 0.04ds Ratio M-H. Random. 25% 1.01 [0.39, 2.6 2.67 [0.38, 5.5 0.55 [0.31, 0.9 0.92 [0.47, 1.7]	0.01		Odds Ratio	 10	
Enkhabi 2018 .ee 2016 .ee 2017 J.2016T Shi 2013 Wang 2016 Zhu 2015 Total (95% C1) Total events Heterogeneity: Chi ² = 1 est for overal effect: Study or Subgroup .ee 2016 .ee 2018b J.2016T	11 15 242 61 49 28 454 8.95, df = I Z = 0.09 (I Z = 0.09 (I N+ Events 9 9 11 11 330	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185 174 162	7 0 59 5 2 2 0.18); ² = 3) N- Events 9 9 4 171	8 94 66 68 15 17 283 33% Total 187 162 194	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% <u>Weight</u> 14.5% 11.8% 19.9%	0.49 [0.18, 1.31 8.07 [0.48, 136.00 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] Odds Ratio M-H. Random, 95% 1.01 [0.39, 2.6 2.67 [0.83, 6.5 0.55 [0.31, 0.9 0.92 [0.47, .17, 1.4] 0.65, 2.0	CI 1) 0.01 CI 1) 5] 8] 7] 8]		Odds Ratio	 10	
Enkhabi 2018 .ee 2016 .ee 2017 J.2016T J.2016T J.2016T Total (95% C1) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: Budy or Subgroup .ee 2016 .ee 2018 .ee 2018 J.2016T Shi 2013 Nang 2016	111 15 242 61 49 28 8.95, df = I Z = 0.09 (I N+ Events 9 11 130 31 27	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185 174 162 71 124	7 0 59 5 2 2 0.18); ² = 3) N- Events 9 4 171 33 27	8 94 66 68 15 17 283 33% Total 187 162 194 72 138	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 18.7% 19.6%	0.49 [0.18, 1.31 6.07 [0.48, 1.36 60 0.80 [0.37, 1.73 1.82 [0.59, 5.53 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] 0.04ds Ratio M-H. Random. 25% 1.01 [0.39, 2.6 2.67 [0.38, 5.5 0.55 [0.31, 0.9 0.92 [0.47, 1.7]	CI 1) 0.01 CI 1) 5] 8] 7] 8]		Odds Ratio	 10	
Enkhabi 2018 .ee 2016 .ee 2017 J.2016T J.2016T J.2016T Total (95% C1) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: Budy or Subgroup .ee 2016 .ee 2018 .ee 2018 J.2016T Shi 2013 Nang 2016	111 15 242 61 49 28 8.95, df = I Z = 0.09 (I N+ Events 9 11 130 31 27	289 270 288 128 247 103 1433 6 (P = 0 P = 0.9 Total 185 174 162 71 124	7 0 59 5 2 2 0.18); ² = 3) N- Events 9 4 171 33 27	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 18.7% 19.6%	0.49 [0.18, 1.31 8.07 [0.48, 136.00 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] Odds Ratio M-H. Random, 95% 1.01 [0.39, 2.6 2.67 [0.83, 6.5 0.55 [0.31, 0.9 0.92 [0.47, .17, 1.4] 0.65, 2.0	0.01 CI 1] 5] 8] 7] 8]		Odds Ratio	 10	→ 100
Enkhabit 2018 .e.e.2016 .e.e.2018 .e.e.2018 Jone 2018 Jone 2018 Prove 2018 Prove 2018 Fortal (99% CI) Total events Fortal revents Fortal revents Fortal revents Study or Subgroup .e.e.2016 Log 2016 Log 2016 Jone 2016	111 15 242 611 49 28 8.95, df = Z = 0.09 (l N+ Events 11 130 31 1 130 31 27 20 228	289 270 288 128 247 103 1433 6 (P = 1 P = 0.9 162 174 162 71 124 52 768	7 0 59 5 2 0.18); I ² = 3) N- Events 9 4 171 33 27 10 254	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 19.6% 15.5% 100.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random. 95% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.71, 2, 1]	0.01 CI 1] 5] 8] 7] 8]		Odds Ratio	 10	→
Enkhabi 2018 .ex 2016 .ex 2016 Joint T Joint T Joint T Joint 2015 Fotal (95% Cl) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: - Study or Subgroup .ex 2016 Joint J Joint J J	111 15 242 611 49 28 8.95, df = 7 2 = 0.09 (f N+ Events 9 11 130 31 27 20 228 0.30; Ch ²	289 270 288 128 247 103 1433 6 (P = I P = 0.9 Total 162 71 124 52 768 = 15.26	7 0 59 5 2 82 0.18); ² = 3) N- Events 9 4 171 33 27 10 254 ; df = 5 (F	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 19.6% 15.5% 100.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random. 95% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.71, 2, 1]	CI 11 13 14 15 15 15 18 18 18 17 18 18 17 18 19 10 10 10 10 10 10 10 10 10 10		Odds Ratio		→
Enkhabi 2018 .ex 2016 .ex 2016 Joint T Joint T Joint T Joint 2015 Fotal (95% Cl) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: - Study or Subgroup .ex 2016 Joint J Joint J J	111 15 242 611 49 28 8.95, df = 7 2 = 0.09 (f N+ Events 9 11 130 31 27 20 228 0.30; Ch ²	289 270 288 128 247 103 1433 6 (P = I P = 0.9 Total 162 71 124 52 768 = 15.26	7 0 59 5 2 82 0.18); ² = 3) N- Events 9 4 171 33 27 10 254 ; df = 5 (F	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 19.6% 15.5% 100.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random. 95% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.71, 2, 1]	0.01 CI 1] 5] 8] 7] 8]		Odds Ratio	 10	
Enkhabi 2018 .ex 2016 .ex 2016 Joint T Joint T Joint T Joint 2015 Fotal (95% Cl) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: - Study or Subgroup .ex 2016 Joint J Joint J J	111 15 242 611 49 28 454 8.95, df = Z = 0.09 (l N+ Events 9 11 130 31 27 20 228 0.30; Chi ² 2 Z = 0.74 (F	289 270 288 128 247 103 1433 6 (P = I P = 0.9 Total 162 71 124 52 768 = 15.26	7 0 59 5 5 2 0.18); I ² = 3) N- Events 171 33 27 10 254 ; df = 5 (F	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 19.6% 15.5% 100.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.64] Odds Ratio M-H. Random, 95% 1.01 [0.39, 26 2.67 [0.83, 6.5 0.55 [0.31, 0.9 0.92 [0.47, 1.7 1.14 [0.63, 20 3.63 [1.51, 6.6 1.23 [0.71, 2.1; 7%	CI 11 13 14 15 15 15 18 18 18 17 18 18 17 18 19 10 10 10 10 10 10 10 10 10 10		Odds Ratio H. Random, 959 H. Random, 950 H. Random,		
Enkhabi 2018 .e.e.2016 .e.e.2018 .e.e.2018 J. 2016T Shi 2013 Nang 2016 Zhu 2015 Total (9% C1) Total events Heterogeneity: Ch ² = 1 Fest for overall effect: Study or Subgroup .e.e.2016 Log 2016 Zhu 2015 Total (9% C1) Total events Total events Total events Test for overall effect: 2	111 15 242 61 49 28 454 8.95, df = 1 Z = 0.09 (f N+ Events 11 130 31 27 20 228 0.30; Chi ² Z = 0.74 (F III.IV	289 270 288 128 247 103 1433 6 (P = 1 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 P = 0.46	7 7 00 59 5 5 2 2 0.18); ² = 2 9 4 171 33 27 10 10 2254 (, df = 5 (F	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 821	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 11.8% 19.9% 19.9% 19.9% 15.5%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 173, 124] 1.42 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] 0.04 Statio M-H. Random, 95% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1, 2, 1] 7% Odds Ratio	CI 0.01 CI 51 81 81 6.01		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabit 2018 e. 2016 e. 2018 e. 2018 e. 2018 J.2016 Thu 2015 Fotal (95% Cl) Total events Heterogeneity: Chi ² = 1 Heterogeneity: Chi ² = 1 Study or Subgroup e. 2016 	11 15 242 61 49 28 454 8.95, df = Z = 0.09 (l N+ Events 9 11 130 31 27 20 228 0.30; Ch ² Z = 0.74 (F ULL) ULL) 228 0.30; Ch ² Z = 0.74 (F ULL) 228 0.30; Ch ² 228 0.30; Ch ² 228 0.30; Ch ² 228 0.30; Ch ² 228 0.30; Ch ² 228 0.30; Ch ² 239 0.30; Ch ² 249 0.30; Ch ² 250 0.30; Ch ² 350 0.30; Ch ²	289 270 288 128 247 103 1433 6 (P = 0.9 Total 185 174 162 768 = 15.26 P = 0.46 768	7 7 0 9 59 5 5 2 2 82 2 82 2 3 3) N- Events 2 7 10 254 (F 5 (F 10) 10 254 (F 5 (F) 10 10 254 (F) 10 10 10 10 10 10 10 10 10 10 10 10 10	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 15.5% 100.0% Weight 0.9%; I ² = 6	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.64] Odds Ratio MH. Random, 95% 1.01 [0.39, 26 2.67 [0.33, 65 0.55 [0.31, 0.9 0.92 [0.47, 1.7 1.14 [0.63, 20 3.63 [1.51, 66 1.23 [0.71, 2.1; 7% Odds Ratio MH. Random, 95%	0.01 CI 11 51 81 71 0.01 CI		Odds Ratio H. Random, 959 H. Random, 950 H. Random,		
Enkhabt 2018 	111 15 242 454 454 454 454 454 454 454 454 45	289 270 288 287 103 1433 6 (P = (P = 0.9 7 185 174 162 71 124 52 768 = 15.26 P = 0.46 7 768	7 7 0 59 5 5 2 2.0.18); I ² = 2 3) N- Events 33 27 10 254 (5); I ² = 5 10 254 (- 5); I ² = 5 10 254 (- 254 - 2); I ² = 5 10 254 (- 2); I ² = 5 10 254 (- 2); I ² = 5 10 254 (- 2); I ² = 5 10 25 25 25 25 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821 ° = 0.00 Total 59	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 19.9% 15.5% 100.0% Weight 13.8%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random, 35% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.74, 2.1] 7% Odds Ratio M-H. Random, 35% 1.22 [0.59, 2.5	CI CI CI CI CI CI CI CI		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 	111 15 242 61 49 242 61 49 9 27 2 0.09 9 9 9 9 9 9 9 9 9 9 9 9 9 130 31 130 31 130 32 20 8 3.030; Chi ⁻ i 20 2 228 8 3.030; Chi ⁻ i 2 2 2 2 2 2 8 9 9 9 2 2 2 2 9 9 9 9 2 2 9 9 9 9	289 270 288 128 247 103 1433 6 (P = 1 1433 6 (P = 0.9 70 185 71 124 52 71 124 52 768 = 15.266 P = 0.46 757 215	7700 5995 5522 0.18): P= Events 4 171 3327 10 25445 4 171 10 25445 10 10 10 10 10 10 10 10 10 10 10 10 10	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821 9 = 0.00 Total 59 173	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 19.9% 19.9% 15.5% 100.0% 19.9% 15.5% 100.0% 19.9% 14.5% 14.7%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.64] 0dds Ratio M-H. Random, 95% 1.01 [0.38, 2.6 2.67 [0.33, 6.5 0.55 [0.31, 0.9 0.92 [0.47, 1.7 1.14 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.71, 2.1] 7% Odds Ratio M-H. Random, 95% 1.22 [0.59, 2.5 1.40 [0.54, 3.6	1 1 1 1 1 1 1 1 1 1 1 1 1 5 1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 e.2016 e.2018 e.2018 e.2018 	111 15 242 454 454 454 454 454 454 454 454 45	289 270 288 289 277 103 1433 6 (P = 1 P = 0.9 70 1433 6 (P = 1 P = 0.9 70 185 174 162 71 124 52 768 = 15.26 P = 0.46 57 215 57 215 32	7 7 0 59 5 5 2 2.0.18); I ² = 2 3) N- Events 33 27 10 254 (5); I ² = 5 10 254 (- 5); I ² = 5 10 254 (- 254 - 2); I ² = 5 10 254 (- 2); I ² = 5 10 254 (- 2); I ² = 5 10 254 (- 2); I ² = 5 10 25 25 25 25 26 26 27 27 27 27 27 27 27 27 27 27 27 27 27	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821 ° = 0.00 Total 59	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 19.9% 15.5% 100.0% Weight 13.8%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random, 35% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 6.6 1.23 [0.74, 2.1] 7% Odds Ratio M-H. Random, 35% 1.22 [0.59, 2.5))))))))))))))		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 	111 115 242 242 261 49 928 454 454 454 454 454 454 454 454 454 45	289 270 288 128 247 103 1433 6 (P = 1 1433 6 (P = 0.9 70 185 71 124 52 71 124 52 768 = 15.266 P = 0.46 757 215	7 7 0 59 5 5 2 82 3 (18); I ² = 8 9 4 171 33 27 10 171 33 25 4 5, df = 5 (F 9 171 171 33 27 10 171 254 4 171 33 27 7 37	8 94 66 88 15 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 19.5% 10.5% Weight 15.5%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.64] 0dds Ratio M-H. Random, 95% 1.01 [0.39, 26 2.67 [0.33, 65 0.55 [0.31, 0.9 0.92 [0.47, 1.7 1.14 [0.63, 20 3.63 [1.51, 65 1.23 [0.71, 2.1] 7% Odds Ratio M-H. Random, 95% 1.23 [0.71, 2.1] 7%	1 1 1 1 1 1 1 1 1 1 1 1 1 1		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 	111 15 242 4242 61 49 9 88.95, df = 1 27 2 = 0.09 (to 88.95, df = 1 2 = 0.09 (to 9 9 11 130 31 130 31 130 31 130 31 130 228 82 20 82 20 82 20 82 20 82 20 82 20 82 20 82 20 82 20 82 20 9 9 11 11 20 20 20 20 82 20 20 20 20 20 20 20 20 20 20 20 20 20	289 270 288 289 128 247 103 1433 6 (P = (P = 0.9 Total 185 174 162 71 124 52 768 = 15.266 P = 0.46 Total 57 215 57 2174	7 7 0 59 5 5 2 2 82 82 82 8 9 4 171 33 3) N- Events 27 10 254 4, df = 5 (F 5 27 7 37 7 34	8 94 66 68 15 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 57	22.6% 1.7% 33.8% 10.4% 16.8% 5.5% 100.0% Weight 14.5% 19.9% 19.9% 19.9% 19.9% 19.9% 19.9% 15.5% 100.0% Weight 18.4% 14.1% 14.4% 11.2%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.80 [0.37, 1.73 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.54] M-H. Random. 35% 1.01 [0.39, 2.6 2.67 [0.38, 55 0.55 [0.31, 0.9 0.92 [0.47, 1.7] 1.4 [0.63, 2.0 3.63 [1.51, 8.6 1.23 [0.71, 2.1] 7% Odds Ratio M-H. Random. 9% 1.22 [0.59, 2.5 1.40 [0.54, 2.5] 1.22 [0.59, 2.5 1.40 [0.54, 2.5])))) 0.01 CC CC CC CC CC CC CC CC CC C		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 e.2016 e.2018 e.2018 e.2018 e.2018 	111 115 242 242 288 88.95, df = 1 8.95, df = 1 20.08 (ft 8.95, df = 1 20.08 (ft 8.95, df = 1 20.08 (ft 130 31 130 31 27 20 228 228 228 228 227 22 228 228 228 227 21 21 21 21 21 21 21 21 21 21 21 21 21	289 270 288 128 128 128 247 103 1433 6 (P = 0.9 P = 0.9 Total 174 162 711 124 52 768 57 215 57 32 177 174 78 124 78 124	7 7 0 59 5 5 2 82 82 3 3) N-Events 9 9 4 171 33 32 7 10 254 4 171 10 254 4 5 (F)) I-III Events 25 5 7 37 37 37 37 37 37 37 37	8 94 66 88 15 15 17 283 33% Total 187 162 194 72 138 68 821 9 = 0.00 70 59 173 57 157 65 138	22.6% 1.7% 1.7% 10.4% 10.4% 10.4% 10.4% 10.0% 100.0% Weight 14.5% 19.9% 19.5% 100.0% 19.7% 18.4% 14.4% 14.4% 14.4% 14.4% 11.4% 15.2% 10.4% 11.1% 1	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03 1.02 (0.68, 1.54) 0.44 (0.16, 1.51 2.80 (0.60, 13.03 1.02 (0.68, 1.54) 0.44 (0.68, 1.54) 0.45 (0.10, 1.54))) 0.01 (Cl (Cl (Cl (Cl (Cl (Cl (Cl (Cl		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabi 2018 	111 15 242 49 49 28 454 49 28 454 49 28 8 454 49 28 8 454 49 28 8 9 9 11 130 31 130 20 228 8 3.30; Chi ² + 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	289 270 288 289 270 288 247 103 1433 6 (P = 1 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 2 = 0.46 57 215 32 215 32 2174 78	7 7 0 59 5 2 2 2. 1.18); P = 3 3) N Events 2 3 3 3 3 3 3 7 10 10 254 4 5 (F = 5 (F) 10 I-II I-II 254 4 37 7 25 7 7 32 8	8 94 66 88 15 15 17 283 33% Total 187 162 194 72 138 68 821 9 = 0.00 70 59 173 57 157 65 138	22.6% 1.7% 1.7% 10.4% 10.4% 10.4% 10.0% Weight 14.5% 100.0% Weight 18.7% 19.9% 15.5% 100.0% Weight 18.7% 11.4% 11.4% 15.2% 11.0% 11.3% 11.5% 11.3%	0.49 (0.18, 1.31 8.07 (0.48, 136.60 0.80 (0.37, 1.73 1.82 (0.59, 5.63 0.49 (0.16, 1.51 2.80 (0.60, 13.03 1.02 (0.68, 1.54) 0.04 (0.16, 1.51 0.04 (0.16, 1.51 0.04 (0.16, 1.54) 0.04 (0.16, 1.54) 0.04 (0.16, 1.54) 0.04 (0.16, 1.54) 0.04 (0.16, 1.54) 0.05 (0.13, 0.9 0.92 (0.47, 1.71 1.14 (0.63, 2.0 3.63 (1.51, 6.6 1.23 (0.71, 2.1) 7% 00 (0.58, 7.6) 0.12 (0.59, 2.5 1.40 (0.54, 2.6) 0.79 (0.32, 1.9 2.58 (0.80, 2.2) 0.40 (0.20, 0.7)))) 0.01 (Cl (Cl (Cl (Cl (Cl (Cl (Cl (Cl		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabt 2018 	11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 1433 6 (P = 1 P = 0.9 70 174 162 71 174 162 768 = 15.266 2 = 0.46 77 71 124 52 768 = 15.262 77 124 680	7 7 0 59 5 2 2 2 18); $ ^2 = 3$ 3) N- Events 133 27 10 254 4, dl = 5 (F 7 37 4 37 28 138	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 (Cl (Cl (Cl (Cl (Cl (Cl (Cl (Cl		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		
Enkhabi 2018 e. 2016 e. 2016 e. 2018 J. 2016T Zhu 2015 Total (95% C1) Total events Test for overall effect: 	11 11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 4433 6 (P = 4 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 P = 0.46 71 124 52 768 = 15.27 8 215 32 215 32 217 4 78 124 6 (P = 1, 0, 1) 768 = 10.41 768 = 10.41 768 768 768 768 768 768 768 768 768 768	7 7 0 59 5 5 2 2 822 822 9 8 9 4 171 33 9 4 171 33 9 4 4 , df = 5 (F 7 7 37 28 25 7 7 38 18 18 18 18 18 18 18 18 18 1	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 (Cl (Cl (Cl (Cl (Cl (Cl (Cl (Cl		Odds Ratio		
Enkhabt 2018 	11 11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 4433 6 (P = 4 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 P = 0.46 71 124 52 768 = 15.27 8 215 32 215 32 217 4 78 124 6 (P = 1, 0, 1) 768 = 10.41 768 = 10.41 768 768 768 768 768 768 768 768 768 768	7 7 0 59 5 5 2 2 822 822 9 8 9 4 171 33 9 4 171 33 9 4 4 , df = 5 (F 7 7 37 28 25 7 7 38 18 18 18 18 18 18 18 18 18 1	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 C1 C1 C1 C1 C1 C1 C1 C1 C1 C		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		100
nkhab (2018) ee 2016 ee 2016 ee 2018) 12016T 13016T 13017 10	11 11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 4433 6 (P = 4 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 P = 0.46 71 124 52 768 = 15.27 8 215 32 215 32 217 4 78 124 6 (P = 1, 0, 1) 768 = 10.41 768 = 10.41 768 768 768 768 768 768 768 768 768 768	7 7 0 59 5 5 2 2 822 822 9 8 9 4 171 33 9 4 171 33 9 4 4 , df = 5 (F 7 7 37 28 25 7 7 38 18 18 18 18 18 18 18 18 18 1	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 C1 C1 C1 C1 C1 C1 C1 C1 C1 C		Odds Ratio		100
nkhab (2018) ee 2016 ee 2016 ee 2018) 12016T 13016T 13017 10	11 11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 4433 6 (P = 4 P = 0.9 Total 185 174 162 71 124 52 768 = 15.26 P = 0.46 71 124 52 768 = 15.27 8 215 32 215 32 217 4 78 124 6 (P = 1, 0, 1) 768 = 10.41 768 = 10.41 768 768 768 768 768 768 768 768 768 768	7 7 0 59 5 5 2 2 822 822 9 8 9 4 171 33 9 4 171 33 9 4 4 , df = 5 (F 7 7 37 28 25 7 7 38 18 18 18 18 18 18 18 18 18 1	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 CC CC CC 0.01 CC CC CC CC CC CC CC CC CC C		Odds Ratio		100
Enkhabt 2018 	11 15 242 242 242 242 242 242 242 24	289 270 288 247 103 1433 6 (P = 1 P = 0.9 70 174 162 71 174 162 768 = 15.266 2 = 0.46 77 71 124 52 768 = 15.262 77 124 680	7 7 0 59 5 2 2 2 18); $ ^2 = 3$ 3) N- Events 133 27 10 254 4, dl = 5 (F 7 37 4 37 28 138	8 94 66 68 15 17 283 33% Total 187 162 194 72 138 68 821 2 = 0.00 Total 59 173 57 157 65 138 649	22.6% 1.7% 1.7% 1.7% 10.4% 10.4% 10.4% 10.5% 100.0% Weight 14.5% 10.6% 10.5% 10.6% 10.7% 10.7% 10.7% 10.7% 10.7% 10.7% 10.0%	0.49 [0.18, 1.31 8.07 [0.48, 136.60 0.60 [0.37, 173 1.82 [0.59, 5.63 0.49 [0.16, 1.51 2.80 [0.60, 13.03 1.02 [0.68, 1.84] 0.04ds Ratio MH. Random. 95% 1.01 [0.39, 26 2.67 [0.83, 85 0.55 [0.31, 09 0.32 [0.71, 2.1] 7% 0.04ds Ratio MH. Random. 95% 1.22 [0.59, 25 1.40 [0.54, 25 1.23 [0.71, 2.1] 7%))) 0.01 CC CC CC 0.01 CC CC CC CC CC CC CC CC CC C		Odds Ratio H. Random. 959 1 N+ N- Odds Ratio		10



pooled result showed no significant association found between PD-L1 expression and TNM stage (OR = 0.98, 95%CI 0.61-1.58, P = 0.94; see Figure 3H).

Heterogeneity was identified in the analysis of PD-L1 expression with cancer location (P = 0.73, $I^2 = 82\%$) and lymph node metastasis (P = 0.46, $I^2 = 67\%$). Therefore, a random effects model was used in the above analyses and other subgroup analyses were performed in a fixed effects model.

Publication Bias


Egger's and Begg's tests showed that no publication bias influencing the HRs for OS was observed in the six studies (Figure 4). The P-values for these tests were 0.683 and 1.000, respectively. In addition, the funnel plots showed no publication bias for gender or T stage (Figure 5).

DISCUSSION

In the present meta-analysis of the clinicopathological and prognostic significance PD-L1 expression in CRC, we found that PD-L1 expression was significantly associated with poor OS in TC. In addition, the pooled results of RFS and DFS showed that PD-L1 expression was significantly correlated with unfavorable clinical outcomes. Poor differentiation and right colon CRC tumors suggested a poor prognosis. The expression of PD-L1 was independent of gender, age, tumor size, T stage, lymph node metastasis, and TNM stage. To our knowledge, this comprehensive meta-analysis is the first to evaluate the association of PD-L1 expression with clinicopathological characteristics and prognostic parameters in colorectal cancer.


During the process of study of selection, the study of Droeser et al. (2013) was excluded for it included unselected, nonconsecutive, primary, sporadic colorectal cancers, and the data of the included articles in this meta-analysis were satisfied with a more rigorous standards, which excluded the patients receiving adjuvant chemotherapy before surgery, diagnosis of gastrointestinal stromal tumor or lymphoma, diagnosis with additional cancers. It is well-known that accurate results were based on the rigorous exclusion criteria in retrospective study. Among the OS data in six included studies, one study showed contradictory results showing that PD-L1 positive expression was significantly associated with better OS. This study was not the only one to report a positive prognostic impact of PD-L1 expression. Sabatier et al. (Schalper et al., 2014) evaluated PD-L1 expression in 5,454 breast cancer cases and found that positive PD-L1 expression was associated with better metastasisfree survival and improved response to chemotherapy. However, the pooled result showed a significant correlation of PD-L1 expression and poor prognostic outcomes was supported by other articles reporting poorer outcomes in renal cell carcinoma, non-small cell lung cancer (Wang et al., 2015) and osteosarcoma (Lussier et al., 2015). This was because of the complex function of PD-L1 in the initiation and growth of CRC.

PD-L1 is upregulated by many inflammatory mediators and cytokines (Keir et al., 2006, 2008; Okazaki and Honjo, 2006) and PD1/PD-L1 binding can induce activated T cell apoptosis, exhaustion, and interleukin-10(IL-10) expression as a negative feedback system (Zou et al., 2016). Moreover, PD-L1 expression can help tumor cells to evade immunosurveillance and enhance the function of Tregs in CRC (Lu et al., 2011; Toh et al., 2016).



However, MSI tumors in CRC display high infiltration with CD8+ cytotoxic T lymphocytes (CTLs) and activated Th1 cells, which may contribute to better survival (Gubin et al., 2014). MSI tumors are also counterbalanced by upregulating expression of multiple immune checkpoints (Angelova et al., 2015; Becht et al., 2016), such as CTL-associated antigen 4 (CTLA4), PD-1, PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1). Upregulated after T cell activation, PD-1 declines when an antigen is cleared. While PD-1 expression remains elevated, as in CRC cancer, T cells enter a state of exhaustion or anergy (Xiao and Freeman, 2015). A study found that Fusobacterium species could evade the high load of neoantigens in MSI colorectal cancer (Tahara et al., 2014). And these species may facilitate upregulation of PD-L1 and lead to poor survival (Kostic et al., 2013). Considering the dynamic changes of PD-L1 expression, our results showing that PD-L1 expression was significantly associated with poor prognoses appear more credible.

We also noticed a recently literature make a contradictory conclusion with our study. This study considered that no significant differences founded in colorectal cancer-specific or overall survival by Tumor Immunity in the MicroEnvironment (TIME) subtypes (Hamada et al., 2018). We found that the primary data of their study were too old, as one cohort was from 1986 to 1992 and the other was from 1986 to 2004 (Giovannucci et al., 1995; Wark et al., 2009). While, our primary data were carried out from 2006 to 2016. The discrepancies between Hamada et al. (2018) and our study might reflect the different storage time of tissue sections. Reports by Bertheau et al. (1998) and Jacobs et al. (1996), who investigated the loss of immunoreactivity for a panel of antibodies in breast carcinomas, neuroendocrine tumors and lymphomas, indicated that for the majority of epitopes tested there is a time-dependent substantial loss in stored tissue slides. CRC develops via sequential genetic and epigenetic alterations of TCs, and is influenced by tumorhost interactions. Because CRC patients easily developed local



recurrences and distant metastases within 5 years after surgical treatment and CRC has typical immune subgroups (Dienstmann et al., 2017), researchers found that immunotherapy is able to reach center stage in the field of second-line therapy in oncology treatment (Topalian et al., 2012; Hon et al., 2018). As one of the types of CRC, high microsatellite instability (MSI-H) can gather TILs and upregulate PD-L1 expression in tumor cells (Herbst et al., 2014).Currently, PD-L1 expression on TCs is considered as an immune-tolerance mechanism of carcinoma, because it can attract PD-1 expressing immune-inhibitory TILs. However, little is known about the complex interrelationship among PD-L1 expression, TILs, and major tumor molecular features. PD-L1 promoter methylation (mPD-L1) was significantly correlated with poor PD-L1 mRNA expression, indicating that PD-L1 expression might be regulated by mPD-L1 on a cellular level in CRC (Goltz et al., 2016). However, this study was not available to provide data on PD-L1 protein expression and there was a study had published a proteomic characterization of the cohort, showing that protein abundance could not be reliably predicted from DNA- or RNA-level measurements (Zhang et al., 2014). Previous studies have shown a significant correlation of PD-L1 expression with OS in melanoma (Robert et al., 2015), breast cancer (Zhang et al., 2017), renal cell carcinoma (Motzer et al., 2014), and non-small cell lung cancer (Zhang et al., 2015), and observed prominent clinical benefits of PD-1/PD-L1 checkpoint blockades in these carcinoma patients. Although previous trials have suggested no role for immunotherapy in patients with CRC, recent studies have demonstrated that MSI-H in CRC did benefit (Kwak et al., 2016; Overman et al., 2017). Therefore, we investigated the relationship between the expression of PD-L1 and clinicopathological factors, and the results showed that poor differentiation and right colon location in CRC were PD-L1 expression positive. In addition, poor differentiation and right colon location in CRC were also significantly correlated with poor prognoses, which were more likely to be MSI-H. Thus, our study provided a scientific rationale and direct support for clinicians to select MSI-H CRC patients for anti-PD-1/PD-L1 immunotherapy.

This study provided moderate evidence to evaluate the association of PD-L1 expression with prognostic outcomes and clinicopathological factors. However, there were some limitations. Firstly, only six included studies evaluated the association of PD-L1 expression with OS. Although the sample sizes of RFS and DFS were relatively small, their results should have alleviated some of these concerns. Secondly, the cut-off values determining positive and negative PD-L1 expression and antibodies for PD-L1 varied among the included studies. Thus, the subgroup of IRS \geq 4 had reduced heterogeneity and addressed some of these concerns. Thirdly, only articles published in English were included. Accordingly, to address these limitations, a large multicenter study with uniform evaluation methods (the same antibody and cut-off for positive PD-L1 expression) may be helpful to attain results that are more accurate. Despite the above limitations, the present meta-analysis demonstrated the association of PD-L1 expression with prognostic outcomes and clinicopathological factors. The findings of this study may lead to improvements in the outcomes of anti-PD-1/PD-L1 therapy through stratifying patients in a more appropriate manner.

CONCLUSION

In conclusion, our results showed that PD-L1 positive expression might be a new biomarker for poor prognosis in CRC. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, especially patients with MSI-H. Well-designed and high-quality studies with uniform evaluation methods are needed to confirm the association of PD-L1 expression in CRC.

AUTHOR CONTRIBUTIONS

YL, MH, and LX designed this study. YZ and MH screened identified studies and extracted data. Disagreements were resolved by discussion with YL and YZ performed the statistical analyses. MH and YZ prepared the figures and tables. YL, MH, and LX reviewed the results, interpreted the data, and wrote the manuscript. All authors have read and approved the final version of this manuscript.

REFERENCES

- Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., et al. (2015). Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. *Genome Biol.* 16:64. doi: 10.1186/s13059-015-0620-6
- Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., et al. (2016). Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. *Clin. Cancer Res.* 22, 4057–4066. doi: 10.1158/1078-0432.CCR-15-2879
- Bertheau, P., Cazalshatem, D., Meignin, V., de Roquancourt, A., Vérola, O., Lesourd, A., et al. (1998). Variability of immunohistochemical reactivity on stored paraffin slides. J. Clin. Pathol. 51, 370–374. doi: 10.1136/jcp.51.5.370
- Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., Tabernero, J., et al. (2017). Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat. Rev. Cancer* 17:79. doi: 10.1038/nrc.2016.126
- Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C., Huber, X., et al. (2013). Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. *Eur. J. Cancer* 49:233. doi: 10.1016/j.ejca.2013.02.015
- Enkhbat, T., Nishi, M., Takasu, C., Yoshikawa, K., Jun, H., Tokunaga, T., et al. (2018). Programmed Cell death ligand 1 expression is an independent prognostic factor in colorectal cancer. *Anticancer Res.* 38, 3367–3373. doi: 10.21873/anticanres.12603
- Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J., and Willett, W. C. (1995). Physical activity, obesity, and risk for colon cancer and adenoma in men. *Ann. Intern. Med.* 122:327. doi: 10.7326/0003-4819-122-5-199503010-00002
- Goltz, D., Gevensleben, H., Dietrich, J., and Dietrich, D. (2016). PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Onco Immunol. 6:e1257454. doi: 10.1080/2162402X.2016.1257454
- Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., et al. (2014). Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. *Nature* 515, 577–581. doi: 10.1038/nature13988
- Hamada, T., Soong, T. R., Masugi, Y., Kosumi, K., Nowak, J. A., da Silva, A., et al. (2018). TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumorinfiltrating lymphocytes in colorectal carcinomas. *Onco Immunol*.7:e1442999. doi: 10.1080/2162402X.2018.1442999
- Hansen, J. D., Du Pasquier, L., Lefranc, M. P., Lopez, V., Benmansour, A., and Boudinot, P. (2009). The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. *Mol. Immunol.* 46, 457–472. doi: 10.1016/j.molimm.2008.10.007
- Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 515:563. doi: 10.1038/nature14011
- Hon, K. W., Abu, N., Ab Mutalib, N. S., and Jamal, R. (2018). miRNAs and lncRNAs as predictive biomarkers of response to FOLFOX therapy in colorectal cancer. *Front. Pharmacol.* 9:846. doi: 10.3389/fphar.2018.00846
- Inaguma, S., Lasota, J., Wang, Z., Felisiak-Golabek, A., Ikeda, H., and Miettinen, M. (2016). Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. *Mod. Pathol.* 30:278. doi: 10.1038/modpathol.2016.185
- Jacobs, T. W., Prioleau, J. E., Stillman, I. E., and Schnitt, S. J. (1996). Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst. 88, 1054–1059.doi: 10.1093/jnci/88.15.1054
- Keir, M. E., Butte, M. J., Freeman, G. J., and Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol. 26, 677–704. doi: 10.1146/annurev.immunol.26.021607. 090331
- Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., et al. (2006). Tissue expression of PD-L1 mediates peripheral T cell tolerance. *Exp. Med.* 2203, 883–895. doi: 10.1084/jem.20051776
- Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., et al. (2013). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 14, 207–215. doi: 10.1016/j. chom. 2013. 07.007

- Kwak, Y., Koh, J., Kim, D. W., Kang, S. B., Kim, W. H., and Lee, H. S. (2016). Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. *Oncotarget* 7, 81778–81790. doi: 10.18632/oncotarget. 13207
- Lee, K. S., Kim, B. H., Oh, H. K., Kim, D. W., Kang, S. B., Kim, H., et al. (2018). Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: implications for prognosis. *Cancer Sci.* 109, 2957–2969. doi: 10.1111/cas.13716
- Lee, L. H., Cavalcanti, M. S., Segal, N. H., Hechtman, J. F., Weiser, M. R., Smith, J. J., et al. (2016). Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. *Modern Pathol.* 29:1433. doi: 10.1038/modpathol.2016.139
- Lee, S. J., Jun, S. Y., Lee, I. H., Kang, B. W., Park, S. Y., Kim, H. J., et al. (2018). CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. *J. Cancer Res. Clin. Oncol.* 144, 1005–1014. doi: 10.1007/s00432-018-2620-x
- Li, Y., Lei, L., Dai, W., Cai, G., Xu, Y., Li, X., et al. (2016). Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. *Mol. Cancer* 15:55. doi: 10.1186/s12943-016-0539-x
- Liu, R., Peng, K., Yu, Y., Liang, L., Xu, X., Li, W., et al. (2018). Prognostic value of immunoscore and PD-L1 expression in metastatic colorectal cancer patients with different RAS status after palliative operation. *BioMed Res. Int.* 2018, 1–8. doi: 10.1155/2018/5920608
- Lu, B., Chen, L., Liu, L., Zhu, Y., Wu, C., Jiang, J., et al. (2011). T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. *Immunol. Res.* 50, 269–275. doi: 10.1007/s12026 – 011-8227-9
- Lussier, D. M., Johnson, J. L., Hingorani, P., and Blattman, J. N. (2015). Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J. Immunother. Cancer 3:21. doi: 10.1186/s40425-015-0067-z
- Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., et al. (2014). Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. *J. Clin. Oncol.* 33, 1430–1437. doi: 10.1200/JCO.2014.59.0703
- Okazaki, T., and Honjo, T. (2006). The PD-1-PD-L pathway in immunological tolerance. *Trends Immunol.* 27, 195–201. doi: 10.1016/j.it.2006.02.001
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A., et al. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol.* 18:1182. doi: 10.1016/S1470-2045(17)30422-9
- Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330. doi: 10.1056/NEJMoa1412082
- Schalper, K. A., Velcheti, V., Carvajal, D., Wimberly, H., Brown, J., Pusztai, L., et al. (2014). *In situ* tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. *Clin. Cancer Res.* 20, 2773–2782. doi: 10.1158/1078-0432.CCR-13-2702
- Shi, S. J., Wang, L. J., Wang, G. D., Guo, Z. Y., Wei, M., Meng, Y. L., et al. (2013). B7-H1 Expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. *PLoS ONE* 8:e76012. doi: 10.1371/journal.pone.0076012
- Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., et al. (2017). Colorectal cancer statistics. *CA Cancer J. Clin.* 67, 104–117. doi: 10.3322/caac.21395
- Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta analyses. *Eur. J. Epidemiol.* 25, 603–605. doi: 10.1007/s10654-010-9491-z
- Tahara, T., Yamamoto, E., Suzuki, H., Maruyama, R., Chung, W., Garriga, J., et al. (2014). Fusobacterium in colonic flora and molecular features of colorectal carcinoma. *Cancer Res.* 74, 1311–1318. doi: 10.1158/0008-5472.CAN-13-1865
- Toh, J. W. T., de Souza, P., Lim, S. H., Singh, P., Chua, W., Ng, W., et al. (2016). The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. *Clin. Colorec. Cancer* 15:285. doi: 10.1016/j.clcc. 2016.07.007

- Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.* 366, 2443–2454. doi: 10.1056/NEJMoa1200690
- Wang, A., Wang, H. Y., Liu, Y., Zhao, M. C., Zhang, H. J., Lu, Z. Y., et al. (2015). The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. *Eur. J. Surg. Oncol.* 41, 450–456. doi: 10.1016/j.ejso.2015.01.020
- Wang, L., Liu, Z., Fisher, K. W., Ren, F., Lv, J., Davidson, D. D., et al. (2017). Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced stage colorectal cancer. *Hum. Pathol.*71, 20–29. doi: 10.1016/j.humpath.2017.07.014
- Wang, L., Ren, F., Wang, Q., Baldridge, L. A., Monn, M. F., Fisher, K. W., et al. (2016). Significance of programmed death ligand 1 (PD-L1) immunohistochemical expression in colorectal cancer. *Mol. Diagn. Ther.* 20, 175–181. doi: 10.1007/s40291-016-0188-1
- Wang, Y., Wang, H., Yao, H., Li, C., Fang, J. Y., and Xu, J. (2018). Regulation of PD-L1: emerging routes for targeting tumor immune evasion. *Front. Pharmacol.* 19:536. doi: 10.3389/fphar.2018.00536
- Wark, P. A., Wu, K., van 't Veer, P., Fuchs, C. F., and Giovannucci, E. L. (2009). Family history of colorectal cancer: a determinant of advanced adenoma stage or adenoma multiplicity? *Int. J. Cancer* 125, 413–420. doi: 10.1002/ijc.24288
- Welch, H. G., and Robertson, D. J. (2016). Colorectal cancer on the decline - why screening can't explain it all. N. Engl. J. Med. 374:1605. doi: 10.1056/NEJMp1600448
- Xiao, Y., and Freeman, G. J. (2015). The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. *Cancer Discov.* 5:16. doi: 10.1158/2159-8290.CD-14-1397

- Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., et al. (2014). Proteogenomic characterization of human colon and rectal cancer. *Nature* 513, 382–387. doi: 10.1038/nature13438
- Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., et al. (2017). Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. *Oncotarget* 8, 31347–31354. doi: 10.18632/oncotarget.15532
- Zhang, Y., Kang, S., Shen, J., He, J., Jiang, L., Wang, W., et al. (2015). Prognostic significance of progracmmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. *Medicine* 94:e515. doi: 10.1097/MD.00000000000515
- Zheng, P., and Zhou, Z. (2015). Human cancer immunotherapy with PD-1/PD-L1 blockade. *Biomark. Cancer* 7, 15–18. doi: 10.4137/BIC.S29325
- Zhu, H., Qin, H., Huang, Z., Li, S., Zhu, X., He, J., et al. (2015). Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. *Int. J. Clin. Exp. Pathol.* 8, 9351–9359.
- Zou, W., Wolchok, J. D., and Chen, L. (2016). PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. *Sci. Transl. Med.* 8:328rv4. doi: 10.1126/scitranslmed.aad7118

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Li, He, Zhou, Yang, Wei, Bian, Christopher and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.